The invention relates to an optimal selection method of gene chip probes for cancer screening. The method is characterized in that the gene chip probes capable of being used for cancer screening are obtained through three stages of constructing a point mutation site (SNV) group, constructing a candidate probe group and verifying and confirming probes on the basis of nucleic acid data of a confirmed case of a selected cancer.

A storytelling interface comprising a map panel and a genealogy panel, and methods for using the same, are described. The storytelling interface facilitates dynamic and automatic scaling and relocation of the map panel based on a user's location within the genealogy panel, which facilitates a continuous scrolling operation to navigate between different sections of the genealogy panel. The storytelling interface facilitates a user receiving, viewing, and interacting with DNA and ethnic communities results determined from DNA testing, and allows a user to navigate through pertinent communities in both time and/or space.

Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of bio -markers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

Methods for diagnosis of sepsis are disclosed. In particular, the invention relates to the use of bio -markers for aiding diagnosis, prognosis, and treatment of sepsis, and to a panel of biomarkers that can be used to distinguish sepsis from noninfectious sources of inflammation, such as caused by traumatic injury, surgery, autoimmune disease, thrombosis, or systemic inflammatory response syndrome (SIRS).

The present invention relates to a computer-implemented method for providing a coverage of an oligonucleotide set for a plurality of nucleic acids. The present invention provides nucleic acid sequences with the generation of probe-hybridized amplicons and/or nucleic acid sequences without the generation of probe-hybridized amplicons, by a combination of oligonucleotides according to match or mismatch information and position information of a forward primer, a probe, and a reverse primer included in an oligonucleotide set, and thus can provide a coverage of the oligonucleotide set for a plurality of nucleic acid sequences, can analyze specificity of the oligonucleotide set, and can modify the sequences of the oligonucleotides included in the oligonucleotide set for the improvement in specificity. According to the present invention, the specificity analysis results can be compared between an oligonucleotide set of an existing product and an oligonucleotide set of a new product, and the specificity change of the oligonucleotide set can be easily monitored.

The present invention relates to a computer-implemented method for providing a coverage of an oligonucleotide set for a plurality of nucleic acids. The present invention provides nucleic acid sequences with the generation of probe-hybridized amplicons and/or nucleic acid sequences without the generation of probe-hybridized amplicons, by a combination of oligonucleotides according to match or mismatch information and position information of a forward primer, a probe, and a reverse primer included in an oligonucleotide set, and thus can provide a coverage of the oligonucleotide set for a plurality of nucleic acid sequences, can analyze specificity of the oligonucleotide set, and can modify the sequences of the oligonucleotides included in the oligonucleotide set for the improvement in specificity. According to the present invention, the specificity analysis results can be compared between an oligonucleotide set of an existing product and an oligonucleotide set of a new product, and the specificity change of the oligonucleotide set can be easily monitored.

A method for searching data includes storing a probe data and a target data expressed in a first orthogonal domain. The target data includes potential probe match data each characterized by the length of the target data. The probe data representation and the target data are transformed into an orthogonal domain. In the orthogonal domain, the target data is encoded with modulation functions to produce a plurality of encoded target data, each of the modulation functions having a position index corresponding to one of the potential probe match data. The plurality of encoded target data is interfered with the probe data in the orthogonal domain and an inverse transform result is obtained. If the inverse transform result exceeds a threshold, information is output indicating a match between the probe data and a corresponding one of the potential probe match data.

The present invention belongs to the field of diagnosis of disease. Thus the present invention is focused on a method and kit and system for quantifying the level of minimal residual disease (MRD) in a subject who has been treated for said disease, as well as a method of treatment of said disease in a subject which comprises a step of quantifying the level of minimal residual diseases, wherein said quantifying comprises: (a) identifying, amplifying and sequencing a nucleotide sequence in a biological sample obtained from said subject after treatment for said disease, wherein the gDNA of said biological sample has an average weight, k, per cell, and wherein said nucleotide sequence is identified using primers and is amplified using an amount, D, to afford a first list of characters; (b) identifying, amplifying and sequencing a nucleotide sequence in a biological sample obtained from a subject with said disease using the same primers as in step (a) to afford a second list of characters; (c) determining, for each first list of characters obtained in step (a), the degree of similarity, DS, with each second list of characters obtained in step (b); (d) selecting, for each first list of characters obtained in step (a), the DS of highest value, DS.sub.HV; (e) adding up the number of first lists of characters obtained in step (a) which have a DS.sub.HV that is greater than a threshold value, T, to obtain L.sub.c; (f) adding up the total number of lists of characters, L.sub.t, in the first list of characters; and (g) calculating the level of minimal residual disease (MRD) according to either of the following formulae:
MRD=(L.sub.c×k)/(L.sub.t×D)
or
MRD=L.sub.c/L.sub.t
or
MRD=L.sub.c×(D/k)/L.sub.t.sup.2.

The present invention belongs to the field of diagnosis of disease. Thus the present invention is focused on a method and kit and system for quantifying the level of minimal residual disease (MRD) in a subject who has been treated for said disease, as well as a method of treatment of said disease in a subject which comprises a step of quantifying the level of minimal residual diseases, wherein said quantifying comprises: (a) identifying, amplifying and sequencing a nucleotide sequence in a biological sample obtained from said subject after treatment for said disease, wherein the gDNA of said biological sample has an average weight, k, per cell, and wherein said nucleotide sequence is identified using primers and is amplified using an amount, D, to afford a first list of characters; (b) identifying, amplifying and sequencing a nucleotide sequence in a biological sample obtained from a subject with said disease using the same primers as in step (a) to afford a second list of characters; (c) determining, for each first list of characters obtained in step (a), the degree of similarity, DS, with each second list of characters obtained in step (b); (d) selecting, for each first list of characters obtained in step (a), the DS of highest value, DS.sub.HV; (e) adding up the number of first lists of characters obtained in step (a) which have a DS.sub.HV that is greater than a threshold value, T, to obtain L.sub.c; (f) adding up the total number of lists of characters, L.sub.t, in the first list of characters; and (g) calculating the level of minimal residual disease (MRD) according to either of the following formulae:
MRD=(L.sub.c×k)/(L.sub.t×D)
or
MRD=L.sub.c/L.sub.t
or
MRD=L.sub.c×(D/k)/L.sub.t.sup.2.

Provided is a design method for dividing primer pairs into reaction containers, the design method showing an optimum division example. The design method for dividing primer pairs into reaction containers has a design step of, for a plurality of target nucleic acids, designing a plurality of primer pairs each composed of two types of primers, an evaluation step of evaluating non-specific amplification inducibility between the primer pairs, and an assignment step of performing an assignment to the reaction containers, based on the non-specific amplification inducibility, such that primer pairs having the non-specific amplification inducibility are not present in the same reaction container. The assignment step has a graph generation step of generating a graph having the primer pairs as vertices and non-specific amplification inducibility as an edge or a data structure equivalent to the graph, a coloring step of applying a solution to a graph coloring problem or the like to the graph to perform coloring such that the vertices adjacent to each other have different colors, and an association step of associating the plurality of colors with the reaction containers to associate the primer pair with the reaction containers of the corresponding colors.